Patents by Inventor Joerg Kaufmann

Joerg Kaufmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210261980
    Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?->3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3?UTR, wherein the 5? UTR is selected from the group comprising a 5? UTR of a gene or a derivative thereof having a nucleotide identity of at least 85%, wherein the gene is selected from the group consisting of MCP-1, RPL12s.c., Ang-2, HSP70, H3.3., Galectin-9, GADD34, EDN1, HSP70m5, E-selectin, ICAM-1, IL-6 and vWF.
    Type: Application
    Filed: February 10, 2021
    Publication date: August 26, 2021
    Inventors: Klaus GIESE, Oliver KEIL, Jörg KAUFMANN
  • Publication number: 20210245542
    Abstract: A method for producing security elements in an image which are not visible to the human eye and which cannot be copied, in particular for checking the authenticity of images. The image is imaged by means of a halftone, the halftone consisting of individual image dots arranged adjacent to each other. This is characterized in that at least one field having a random geometric shape or freeform is defined in the image/the halftone. By means of manipulation of image dots in the field and/or by means of manipulation of the entire field, an encrypted information that cannot be copied is stored for comparison with at least one database and the serial number is displayed by means of contours formed in the halftone.
    Type: Application
    Filed: June 22, 2019
    Publication date: August 12, 2021
    Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
  • Publication number: 20210248369
    Abstract: A method for checking the authenticity of products, by checking an image (A) of a product. The proof of authenticity is not visible to the human eye and cannot be copied. This is characterized in that a code stored in a halftone image by manipulation of dots and/or a manipulated field bounded in the halftone image can be read by means of an optical device and compared with a retrievable value in at least one database. In at least one field (F1 to F5) a part of a serial number is determined which describes the structure of the serial number and a hash function used for transmitting the serial number to the database, and this is also characterized in that the serial number is subsequently assembled and encrypted with the corresponding hash function.
    Type: Application
    Filed: June 22, 2019
    Publication date: August 12, 2021
    Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
  • Publication number: 20210062198
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 4, 2021
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 10774332
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 15, 2020
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20200144685
    Abstract: A battery cell in the form of a round cell, having: at least one electrode element having an inner side and an outer side and at least one temperature control element, wherein the inner side of the at least one electrode element is spaced apart, at least in sections, from the outer side of the at least one electrode element by means of the temperature control element.
    Type: Application
    Filed: November 4, 2019
    Publication date: May 7, 2020
    Applicant: Volkswagen Aktiengesellschaft
    Inventors: Volker Hohm, Bastian Schaar, Frank Wesche, Joerg Kaufmann, Helge Herten
  • Publication number: 20190390201
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 3, 2019
    Publication date: December 26, 2019
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20190346439
    Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.
    Type: Application
    Filed: July 26, 2019
    Publication date: November 14, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
  • Patent number: 10329568
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10323246
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 18, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10266829
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 23, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20190038557
    Abstract: The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y? is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individually
    Type: Application
    Filed: February 14, 2018
    Publication date: February 7, 2019
    Inventors: Oliver KEIL, Jörg KAUFMANN, Volker FEHRING, Ute SCHAEPER
  • Publication number: 20190024089
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20180291381
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 11, 2018
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20180223286
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: August 15, 2017
    Publication date: August 9, 2018
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 9790505
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 17, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9790501
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 17, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9783802
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 10, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9758784
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: September 12, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20170247697
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 31, 2017
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE